INTRODUCTION
Chronic venous disease (CVD) of the lower limbs is a condition of the venous system in which venous hypertension may cause various symptoms and signs that may include (in the order of severity, greatest to least): pain, swelling, oedema, skin changes, subcutaneous tissue fibrosis and ulcerations [1] . In CVD, normal venous pressure is increased and the return of blood is impaired via several mechanisms, such as structural or functional alteration of the vein walls, valvular incompetence of deep, superficial or perforator veins, venous obstruction or a combination of these [1] . Occurring more frequently in women than in men, CVD is a common medical condition that has a significant impact on patients' quality of life (QoL) and the healthcare system [1, 2] .
Inflammatory processes have demonstrated involvement in structural remodelling of venous valves and the vein wall, leading to valvular incompetence and the development of varicose veins [3] . Various factors can lead to inflammation of the vessel wall. The venous system of the lower limbs undergoes frequent postural pressure changes; however, prolonged periods of sitting or standing can lead to venous stasis, which causes vein distension and valve distortion. Leakage of blood through these damaged valves leads to flow reversal, which in turn initiates endothelial and leukocyte activation [4] . These inflammatory stresses, when repeated over time, eventually lead to chronic recurrent injury to the venous wall, perpetuating inflammation at the vein level [4] .
A second significant pro-inflammatory factor is altered shear stress. Normal shear stress, or steady laminar blood flow, promotes the release of factors that reduce inflammation and the formation of reactive free radicals [1] . In contrast, low or zero shear stress (disturbed or turbulent flow and especially reversal of the direction of blood flow) induces venous inflammation and thrombosis [1] . The endothelium, particularly the endothelial glycocalyx (the carbohydrate-rich layer of proteoglycans and glycoprotein lining the vascular endothelium) [5] , is responsible for translating biomechanical forces into protective biochemical signals (e.g. the production of the vasodilator nitric oxide) [1, 5] . Almost all of the mechanical stress caused by luminal flow is transferred to the glycocalyx, thus virtually eliminating the shear stress at the surface of the venular endothelium [1] . The glycocalyx also inhibits leukocyte adhesion by masking cell adhesion molecules [1] . However, the glycocalyx may be damaged by inflammation which may alter responses to shear stress and result in further leukocyte adhesion. Irrespective of the trigger for inflammatory events in venous valves and walls, various inflammatory mediators and growth factors are released. These include chemokines, cytokines, matrix metalloproteinases, vascular cell adhesion molecule-1, intercellular adhesion molecule-1, transforming growth factor beta, fibroblast growth factor beta and vascular endothelial growth factor [4, 6] . Together, these inflammatory mediators and growth factors perpetuate inflammation, leading to structural remodelling of vein walls and valves, venous dilation, varicose veins and ulceration [6] .
Early treatment for the prevention of venous hypertension and the inhibition of the inflammatory cascade, especially leukocyte-endothelium interactions, could alleviate symptoms of CVD and slow or prevent disease progression to chronic venous insufficiency (CVI) and ulcers [1, 3] . The current recommended first-line treatment of CVD involves conservative measures, such as lifestyle modifications and compression therapy, with frequent addition of veno-active drugs for the treatment of CVD-related symptoms [4, 7] . Interventional therapy is only considered for the treatment of specific signs and symptoms or if conservative therapy fails [7] .
Sulodexide is a specific glycosaminoglycan (GAG), composed of a fast-moving heparin fraction (80%) with affinity for antithrombin III, and a dermatan sulphate fraction (20%) with affinity for heparin cofactor II [8] . Sulodexide exerts a strong anti-thrombotic activity by simultaneously potentiating the antiprotease activities of both antithrombin III and heparin cofactor II [8] . Sulodexide also has a profibrinolytic effect (via activation of tissue plasminogen activator and inhibition of plasminogen activator inhibitor), an antiproliferative effect on smooth muscle cells and antilipaemic and antiatherosclerotic effects [8] .
Several clinical studies have demonstrated the efficacy of sulodexide in the treatment or prevention of vascular diseases associated with increased thrombotic risk, such as peripheral arterial occlusive diseases [9, 10] , post-myocardial infarction [11] , recurrent deep vein thrombosis [12, 13] and post-thrombotic syndrome [14, 15] .
More recently, the antiplatelet [16] and anti-inflammatory [17] activities of sulodexide have been highlighted, together with its significant protective effect on the glycocalyx layer [18] . This suggests that the administration of sulodexide in patients with CVD may interfere with the pathogenesis of the disease, not only when it is linked to previous deep vein thrombosis ( 
RESULTS

Patients
A total of 450 patients were included in the study, mostly from urban (92.9%) rather than rural (7.1%) areas. The mean age (±SD) of patients was 46.9 ± 10.5 years (range 17-78 years); 53.0% were [45 years and three patients were [70 years (older than the upper limit of 70 years specified for the study). A higher proportion of patients were females (65.4%). A total of 436 patients (96.9%) completed the study by attending the final visit at 3 months after enrolment. Reasons for failing to complete the study included withdrawal from the study because of adverse events (specifically, epigastric pain and gastric pain with vomiting; 2 patients) and loss to follow-up for unknown reasons (12 patients).
Efficacy
Symptoms
The number and percentage of patients with each score for subjective and objective symptoms at both T0 and T3 are reported in Table 1 . The number of patients with data available from both visits varied from 430 patients for leg heaviness to 410 patients for erythema.
Three months of treatment with sulodexide significantly improved all subjective and objective symptoms: the median improvement for all symptoms was 1 unit on the Likert scale, meaning median values shifted from severe to moderate for leg heaviness and pain and from moderate to absent for all other symptoms. Mean symptom scores at baseline and at the final visit are shown in Fig. 1 . All improvements were statistically significant (p\0.0001). Mean compound scores at T0 and T3 and their percent reduction at T3 compared with T0, calculated for each patient, are summarised in which was directly proportional to its initial intensity (Fig. 1) . and to sleep and mental symptoms (mean improvement of 40%) ( Table 2) . Changes were statistically significant in each of the four subgroups, in which patients were stratified by age and gender (p\0.0001). No statistically significant differences were observed between the subgroups (p[0.05).
Quality of Life
Safety
Adverse events were spontaneously reported by two patients (epigastric pain and gastric pain with vomiting). However, other patients were not systematically asked about adverse events so no other data are available.
DISCUSSION
In our study, administration of oral sulodexide for 3 months to 450 adult patients with CVD in a setting of real-life clinical practice led to statistically significant improvements in the subjective (heaviness, pain, cramps and paresthesias) and objective (erythema, skin temperature and induration) symptoms as well as patients' QoL compared with baseline. Lower scores represent better conditions (s) heaviness, pain, cramps, paresthesias, erythema, skin temperature, induration (f) pain-related, functional general and functional specific 1-8 (details in Fig. 2 ) (m) sleep-related and mental 1-9 (details in Fig. 3) 2 months as the primary endpoint [20] . Lower scores in the CIVIQ mean better quality of life reduction in the severity of disease, for example after treatment, is reflected in the QoL [7] . Our data show that 3 months of treatment with sulodexide significantly improved the QoL of patients with CVD in pain-related and functional items as well as in sleep and mental items.
Since our study is the first evaluating the effects of sulodexide in CVD patients using a validated questionnaire for the measurement of QoL, comparisons can only be made with studies carried out with other phlebotropic drugs. In a large prospective international, multicentre study, that was non-comparative as far as treatment is concerned, QoL was evaluated using the CIVIQ questionnaire in more than 3600 patients with CVI. Treatment with 1000 mg of micronized purified flavonoid fraction administered daily for 6 months resulted in a significant improvement of QoL, which was greater after 2 months of treatment, but with further improvements after 4 and [21] .
In our study, treatment with sulodexide showed significant improvement from baseline of both QoL and clinical symptoms after 3 months of treatment in an adequate number of patients. However, no control group was used, which is a significant limitation of the study, and caution should be exercised in the evaluation of the results as improvements may be in part due to a greater care to which the patients included in clinical trials are subjected. Nevertheless, it should be noted that the changes in symptoms and signs reported in similar randomised, controlled studies moved in the same favourable direction. In our study the response to sulodexide treatment was assessed by evaluating some important subjective and objective symptoms of CVD using the 4-point Likert-type scale. However, no widely accepted classification of CVD, such as the CEAP classification [27] , was referred to, which is another limitation of the study. Also, the lack of a systematic active collection of tolerability data was a clear limitation of the study. Treatment emergent adverse events were only recorded if spontaneously reported by the study patients. However, the clinical experience with sulodexide in patients with CVD shows that the drug is generally well tolerated [14, 15, 19, 20, [28] [29] [30] [31] [32] [33] [34] [35] .
CONCLUSIONS
In spite of the limitations, our data on more than 400 patients provide additional support for the use of sulodexide in patients with CVD. 
